Trinity compound research profile
PTD-DBM
PTD-DBM stands for "protein transduction domain–Dishevelled binding motif" — a mouthful, but basically it's a lab-made fusion peptide, meaning scientists...
Research overview
PTD-DBM stands for "protein transduction domain–Dishevelled binding motif" — a mouthful, but basically it's a lab-made fusion peptide, meaning scientists stitched two different functional pieces together. One piece (the PTD) acts like a key that lets the peptide slip inside cells, and the other piece (the DBM) is designed to interfere with a specific protein interaction related to hair growth. It was developed by researchers at Yonsei University in South Korea studying why hair follicles shrink and stop growing in balding scalps.
Mechanism under study
Imagine a protein called CXXC5 acting like a brake pedal that normally slows down hair growth signals in your scalp; PTD-DBM works by sneaking in and blocking that brake from being pressed, which lets a growth-promoting pathway called Wnt/beta-catenin run more freely. When that pathway stays switched on, hair follicles are encouraged to grow and even new follicles can form during wound healing in mice (Lee SH et al. 2017).
Human evidence summary
No human clinical trials of PTD-DBM have been identified anywhere in the published research. Everything known about whether it actually regrows hair in real people is still theoretical, based only on lab and animal data, plus scattered personal reports online.
Preclinical evidence summary
In mice, applying PTD-DBM to the skin stimulated hair to regrow and also triggered the formation of entirely new hair follicles during wound healing — a process scientists call "wound-induced hair neogenesis" (PMID 28595998). Combining it with a drug called valproic acid (normally used for bipolar disorder, but which also activates the same growth pathway) made the effect even stronger. Later mouse research extended the findings to hair loss caused by the hormone DHT and a related inflammatory molecule called PGD2 (Cells 2023). Notably, the same research team then moved on to develop a different, drug-like small molecule (called KY19382) instead of continuing with the peptide itself — which hints that even the original scientists saw the peptide as a stepping stone rather than a final product.
Source material
Use the linked publications and records to evaluate study design, population, limitations, and relevance.